The leading hospital chain appoints Lokesh Taridalu Shivakumar as Facility Director for Yeshwanthapur hospital
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
The inspection is now closed, and no regulatory action has been recommended
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The first of four planned modules at the new plant is expected to come online by summer 2026
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Subscribe To Our Newsletter & Stay Updated
